Spark Therapeutics (NASDAQ:ONCE) had its price target hoisted by analysts at SunTrust Banks to $113.00 in a report issued on Thursday, The Fly reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. SunTrust Banks’ price objective points to a potential upside of 102.65% from the company’s current price.
ONCE has been the topic of several other research reports. Cantor Fitzgerald dropped their price objective on Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating on the stock in a research note on Friday, October 13th. Cowen reissued a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Raymond James Financial reissued a “buy” rating and issued a $75.00 price objective on shares of Spark Therapeutics in a research note on Thursday, December 7th. Barclays increased their price objective on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research note on Friday, October 13th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $100.00 target price on shares of Spark Therapeutics in a research report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the company. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $76.53.
Spark Therapeutics (NASDAQ ONCE) opened at $55.76 on Thursday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75. The stock has a market capitalization of $2,060.00 and a P/E ratio of -7.74.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period last year, the company earned ($1.07) EPS. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. equities analysts anticipate that Spark Therapeutics will post -7.58 earnings per share for the current fiscal year.
In other news, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $83.30, for a total value of $416,500.00. Following the completion of the sale, the insider now owns 215,000 shares of the company’s stock, valued at approximately $17,909,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Faga sold 7,500 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $80.96, for a total value of $607,200.00. Following the completion of the sale, the insider now directly owns 6,000 shares of the company’s stock, valued at approximately $485,760. The disclosure for this sale can be found here. Insiders have sold a total of 62,309 shares of company stock worth $4,621,085 in the last ninety days. Insiders own 7.30% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares in the last quarter. BlackRock Inc. boosted its position in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Spark Therapeutics in the 3rd quarter worth $13,519,000. Ameriprise Financial Inc. raised its stake in Spark Therapeutics by 6.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after acquiring an additional 11,785 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in Spark Therapeutics in the 3rd quarter worth $5,286,000. 94.91% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/04/spark-therapeutics-once-pt-raised-to-113-00.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.